Risks Exaggerated, Premarin Still Viable
HMB431 Major Paper
3/16/2011
The risks and benefits of horm champion transposition therapy (HRT) has been a topic of much debate in the juvenile decade. The most widely known HRT drug is Premarin, before long sold by Pfizer. Initially, Premarin was advertised as a drug that could keep women young and feminine after the onset of climacteric1. However, findings from a Womens Health Initiative (WHI) study in 2002 suggested that HRT increases a patients risk of developing cardiovascular disease (CVD) and breast tail assemblycer2. These results comfortably decreased the prescription of the drug, and raised a lot of brawl about the viability of HRT as a drug for postmenopausal women3. Despite the recent controversy, there is a strong military control case for Premarin4,5,6,7. To demonstrate the viability of Premarin, the scientific background of Premarin, a air analysis, and opposing views from various individuals within the industry will be used.
Scientific Background
Hormone replacement has been the leading treatment for women experiencing symptoms associated with menopause since the launch of Premarin in 1942 by Wyeth. Women entering menopause give the bounce experience serious symptoms due to the declining levels of estrogen in the body.
Premarins tool of action, its studied effects on serum lipid composition, tog out mineral density, hypertension, and cognitive function will be discussed below to prove that Premarin is efficient in treating menopausal symptoms.
The female reproductive systems development and maintenance is largely ground on the proper functioning of a family of hormones, especial the secretion of estrogens which is depleted during menopause and which is replaced during HRT with Premarin. This decline in estrogens levels can have mild or severe symptoms for some women. For example, one of the most common symptoms associated with menopause are hot flashes-which is caused by...
If you want to get a full essay, wisit our page: write my paper
No comments:
Post a Comment